

CD14 upregulation as a distinct feature of non-alcoholic fatty liver disease after pancreatoduodenectomy

Daisuke Satoh, Takahito Yagi, Takeshi Nagasaka, Susumu Shinoura, Yuzo Umeda, Ryuichi Yoshida, Masashi Utsumi, Takehiro Tanaka, Hiroshi Sadamori, Toshiyoshi Fujiwara

Daisuke Satoh, Takahito Yagi, Takeshi Nagasaka, Susumu Shinoura, Yuzo Umeda, Ryuichi Yoshida, Masashi Utsumi, Hiroshi Sadamori, Toshiyoshi Fujiwara, Department of Gastroenterological Surgery, Transplant, and Surgical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan
Takehiro Tanaka, Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan

Author contributions: Satoh D performed the majority of experiments; Yagi T, Nagasaka T, Shinoura S, Umeda Y, Yoshida R, Utsumi M, Tanaka T and Sadamori H were involved in editing the manuscript; Satoh D and Fujiwara T designed the study and wrote the manuscript.

Correspondence to: Daisuke Satoh, MD, Department of Gastroenterological Surgery Transplant, and Surgical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan. ddd4863@gmail.com

Telephone: +81-86-2357257 Fax: +81-86-2218775

Received: June 5, 2012 Revised: October 20, 2012

Accepted: November 25, 2012

Published online: April 27, 2013

Abstract

AIM: To investigate the pathogenesis of non-alcoholic fatty liver disease (NAFLD) after pancreatoduodenectomy (PD).

METHODS: A cohort of 82 patients who underwent PD at Okayama University Hospital between 2003 and 2009 was enrolled and the clinicopathological features were compared between patients with and without NAFLD after PD. Computed tomography (CT) images were evaluated every 6 mo after PD for follow-up. Hepatic steatosis was diagnosed on CT when hepatic attenuation values were 40 Hounsfield units. Liver biopsy was performed for 4 of 30 patients with NAFLD after PD who consented to undergo biopsies. To compare

NAFLD after PD with NAFLD associated with metabolic syndrome, liver samples were obtained from 10 patients with NAFLD associated with metabolic syndrome [fatty liver, $n = 5$; non-alcoholic steatohepatitis (NASH), $n = 5$] by percutaneous ultrasonography-guided liver biopsy. Double-fluorescence immunohistochemistry was applied to examine CD14 expression as a marker of lipopolysaccharide (LPS)-sensitized macrophage cells (Kupffer cells) in liver biopsy specimens.

RESULTS: The incidence of postoperative NAFLD was 36.6% (30/82). Univariate analysis identified cancer of the pancreatic head, sex, diameter of the main pancreatic duct, and dissection of the nerve plexus as factors associated with the development of NAFLD after PD. Those patients who developed NAFLD after PD demonstrated significantly decreased levels of serum albumin, total protein, cholesterol and triglycerides compared to patients without NAFLD after PD, but no glucose intolerance or insulin resistance. Liver biopsy was performed in four patients with NAFLD after PD. All four patients showed moderate-to-severe steatosis and NASH was diagnosed in two. Numbers of cells positive for CD68 (a marker of Kupffer cells) and CD14 (a marker of LPS-sensitized Kupffer cells) were counted in all biopsy specimens. The number of CD68+ cells in specimens of NAFLD after PD was significantly increased from that in specimens of NAFLD associated with metabolic syndrome specimens, which indicated the presence of significantly more Kupffer cells in NAFLD after PD than in NAFLD associated with metabolic syndrome. Similarly, more CD14+ cells, namely, LPS-sensitized Kupffer cells, were observed in NAFLD after PD than in NAFLD associated with metabolic syndrome. Regarding NASH, more CD68+ cells and CD14+ cells were observed in NASH after PD specimens than in NASH associated with metabolic syndrome. This showed that more Kupffer cells and more LPS-sensitized Kupffer cells were present in NASH after PD than in NASH associated with metabolic syndrome. These observations suggest that

after PD, Kupffer cells and LPS-sensitized Kupffer cells were significantly upregulated, not only in NASH, but also in simple fatty liver.

CONCLUSION: NAFLD after PD is characterized by both malnutrition and the up-regulation of CD14 on Kupffer cells. Gut-derived endotoxin appears central to the development of NAFLD after PD.

© 2013 Baishideng. All rights reserved.

Key words: Non-alcoholic fatty liver disease; Pancreatoduodenectomy; CD14; Endotoxin; Kupffer cells

Satoh D, Yagi T, Nagasaka T, Shinoura S, Umeda Y, Yoshida R, Utsumi M, Tanaka T, Sadamori H, Fujiwara T. CD14 upregulation as a distinct feature of non-alcoholic fatty liver disease after pancreatoduodenectomy. *World J Hepatol* 2013; 5(4): 189-195 Available from: URL: <http://www.wjgnet.com/1948-5182/full/v5/i4/189.htm> DOI: <http://dx.doi.org/10.4254/wjh.v5.i4.189>

INTRODUCTION

The prevalence of non-alcoholic fatty liver disease (NAFLD) associated with metabolic syndrome is increasing worldwide^[1,2]. NAFLD associated with metabolic syndrome is considered to be associated with chronic over-nutrition that results in the accumulation of visceral fat and obesity and is one of the most common forms of chronic liver disease^[3]. NAFLD associated with metabolic syndrome is related to states such as severe obesity, impairment of glucose tolerance and hyperlipidemia^[4]. Indeed, several studies have shown strong relationships among NAFLD associated with metabolic syndrome, hepatic insulin resistance and type 2 diabetes mellitus^[5-7].

On the other hand, NAFLD sometimes develops after pancreatoduodenectomy (PD)^[8]. Tanaka *et al*^[9] recently reported that NAFLD after PD was characterized by non-obesity and a lack of both hyperlipidemia and insulin resistance. The pathogenesis of NAFLD after PD may thus differ from the pathogenesis of NAFLD associated with metabolic syndrome.

Recently, Tilg *et al*^[10] proposed a new model, suggesting that many hits may act in parallel to finally result in liver inflammation, with gut and adipose tissue-derived factors in particular playing a central role. It was reported that the clinical features of the patients with NAFLD after PD are similar to those found in the murine non-alcoholic steatohepatitis (NASH) model induced by a methionine-choline-deficient (MCD) diet^[9]. In mice fed the MCD diet, portal endotoxemia due to an impaired gut barrier caused by the MCD diet was observed^[11]. We therefore hypothesized that gut-derived lipopolysaccharide (LPS) was associated with NAFLD after PD. LPS might trigger the release of inflammatory cytokines from Kupffer cells, in turn mediating severe hepatic steatosis and liver injury after PD. The process by which LPS acti-

vates Kupffer cells seems to be mediated by LPS-binding protein, CD14 and toll-like receptor 4^[12]. We therefore focused on the CD14 expression on Kupffer cells from liver specimens in cases of NAFLD after PD.

We examined the prevalence, clinical and histological features, and expression of CD14 as a marker of LPS-sensitized Kupffer cells in liver tissues obtained from patients with either NAFLD associated with metabolic syndrome or NAFLD after PD.

MATERIALS AND METHODS

Between February 2003 and August 2009, a total of 100 patients underwent PD at Okayama University Hospital, Okayama, Japan. Of these, 18 patients were excluded from the study because they were unavailable for regular follow-up computed tomography (CT) of the abdomen. The remaining 82 patients (49 men and 33 women) were enrolled in this study. There were no patients with preoperative NAFLD, based on CT and laboratory findings. The mean age at the time of surgery was 63 years (range 31-85 years). Histological diagnosis was pancreatic carcinoma in 32 patients, intraductal papillary-mucinous neoplasm in 27, bile duct carcinoma in 3, and others in 20. In terms of surgical procedures, conventional PD was employed for 73 patients and pylorus-preserving PD for 9 patients. For patients with adenocarcinoma of the pancreatic head, we routinely performed dissection of the nerve plexus around the superior mesenteric artery (SMA), leaving the left side of the SMA near the origin intact. A modification of Child's method was employed for digestive reconstruction.

Body mass index (BMI) was determined for all patients and blood examinations were performed before and every 3 mo after PD. Follow-up continued for more than 12 mo in all cases. Routine blood examinations included fasting lipid, blood glucose and insulin levels, and levels of hemoglobin (HbA1c), aspartate aminotransferase (AST), alanine aminotransferase, total protein, albumin and cholinesterase.

CT images were obtained using a 16-multidetector CT scanner (GE Yokogawa, Tokyo, Japan) without intravenous contrast medium. The raw data set was reconstructed at 5 mm thickness. CT images were evaluated every 6 mo after PD for follow-up. Hepatic steatosis was diagnosed on CT when hepatic attenuation values were 40 Hounsfield units. According to this criterion, 30 of 82 patients who underwent PD were found to have newly appearing hepatic steatosis.

Liver biopsy was performed for 4 of 30 patients with NAFLD after PD who consented to undergo biopsies (fatty liver, $n = 2$; NASH, $n = 2$); in these two men and two women, the mean age was 61 (52-73) years, histological diagnosis was pancreatic carcinoma in one patient, intraductal papillary-mucinous neoplasm in two, and serous cyst adenoma in one, and all of them underwent PD. To compare NAFLD after PD with NAFLD associated with metabolic syndrome, liver samples were obtained from

Table 1 Comparison between pre- and intra-operative data between patients with and without non-alcoholic fatty liver disease after pancreatoduodenectomy

	Non-NAFLD (<i>n</i> = 52)	NAFLD (<i>n</i> = 30)	<i>P</i> value ¹
BMI (kg/m ²)	21.7 ± 3.3	21.4 ± 2.6	0.622
Age (yr)	63.6 ± 10.9	63.4 ± 11.9	0.940
Pancreatic head cancer (yes)	31%	53%	< 0.001 ²
Sex (male)	69%	43%	0.035 ²
Diameter of MPD (mm)	3.9 ± 3.2	5.6 ± 3.2	0.025
Total cholesterol (mg/dL) ³	188.2 ± 53.3	202.0 ± 39.9	0.238
Triglycerides (mg/dL) ³	119.8 ± 69.2	139.9 ± 74.8	0.363
Total protein (g/dL) ³	8.0 ± 0.9	8.3 ± 0.5	0.322
Albumin (g/dL) ³	4.0 ± 0.4	4.0 ± 0.5	0.761
Cholinesterase (U/L) ³	230.6 ± 88.2	244.5 ± 104.9	0.531
Insulin (μU/mL) ³	5.5 ± 2.3	7.7 ± 3.5	0.500
HOMA-IR ³	1.6 ± 1.0	3.2 ± 3.4	0.324
HbA1c (%) ³	5.5 ± 0.8	6.2 ± 1.8	0.060
ALT ³	65.6 ± 0.8	79.9 ± 107.3	0.506
Operation (PPPD)	15%	10%	0.738 ²
Operation time (min)	400.9 ± 49.0	394.6 ± 37.8	0.544
Intraoperative blood loss (mL)	425.2 ± 171.9	419.3 ± 155.6	0.878
Patients with nerve plexus dissection	15%	93%	< 0.001 ²
Pancreatic resection line (SMA)	19%	37%	0.081 ²

¹*P* values calculated using the χ^2 test; ²*P* values calculated using Fisher's exact test; ³Values represent mean ± SD unless otherwise indicated. NAFLD: Non-alcoholic fatty liver disease; BMI: Body mass index; MPD: Main pancreatic duct; HOMA-IR: Homeostasis model assessment for insulin resistance; HbA1c: Hemoglobin A1c; ALT: Alanine aminotransferase; PPPD: Pylorus preserving pancreaticoduodenectomy; SMA: Superior mesenteric artery.

10 patients with NAFLD associated with metabolic syndrome (fatty liver, *n* = 5; NASH, *n* = 5) by percutaneous ultrasonography-guided liver biopsy; these four men and six women had a mean age of 52 (40-64) years. In 10 patients, NAFLD associated with metabolic syndrome was diagnosed by the following criteria: (1) the absence of regular intake of alcohol and past history of abdominal surgery; (2) negative results for hepatitis B virus surface antigen and anti-hepatitis C virus antibodies; and (3) the absence of other types of chronic liver disease.

Specimens were fixed in 40 g/L neutral-buffered formaldehyde, cut at 4 μm thickness and stained using hematoxylin and eosin or the Azan-Mallory method. Histological findings were assessed in a blinded fashion by an independent pathologist. Histological diagnosis of NASH was made based on the presence of macrovesicular steatosis, hepatocyte ballooning and lobular inflammation.

For double immunofluorescence, tissue array slides were deparaffinized and soaked in 0.01 mol/L citrate buffer (pH 6.0) at 90 °C for 30 min for antigen retrieval. Samples were treated with 10 mg/mL bovine serum albumin (BSA) to inhibit non-specific antibody binding, then incubated with primary murine monoclonal antibody to CD68 (Kp-1, dilution 1:500; Dako, Glostrup, Denmark) for 1 h at 37 °C. After washing three times with phosphate-buffered saline (PBS) (pH 7.2), samples were incubated with Cy5-labeled secondary rabbit polyclonal antibody to murine immunoglobulin G for 30 min at 37 °C. For the second immunoreaction, a similar procedure was used:

Table 2 Comparison of postoperative data between patients with and without non-alcoholic fatty liver disease after pancreatoduodenectomy

	Non-NAFLD (<i>n</i> = 52)	NAFLD (<i>n</i> = 30)	<i>P</i> value ¹
BMI (kg/m ²) ²	20.1 ± 3.5	17.4 ± 2.8	0.004
Total cholesterol (mg/dL) ²	159.2 ± 40.4	133.3 ± 36.4	0.011
Triglycerides (mg/dL) ²	102.2 ± 36.4	84.9 ± 49.0	0.169
Total protein (g/dL) ²	7.0 ± 0.7	6.1 ± 0.7	< 0.001
Albumin (g/dL) ²	4.0 ± 0.5	3.1 ± 0.7	< 0.001
Cholinesterase (U/L) ²	215.5 ± 78.5	156.9 ± 88.1	0.006
Insulin (μU/mL) ²	9.7 ± 9.8	4.1 ± 3.8	0.009
HOMA-IR ²	3.1 ± 3.3	1.3 ± 1.2	0.117
HbA1c (%) ²	5.5 ± 0.9	5.6 ± 0.9	0.589
ALT ²	31.6 ± 18.5	52.0 ± 45.1	0.033
Insulin treatment	12%	27%	0.126

¹*P* values calculated using the χ^2 test; ²Measured 6 mo postoperatively. Values represent mean ± SD unless otherwise indicated. NAFLD: Non-alcoholic fatty liver disease; BMI: Body mass index; HOMA-IR: Homeostasis model assessment for insulin resistance; HbA1c: Hemoglobin A1c; ALT: Alanine aminotransferase.

samples were treated with 10 mg/mL BSA, then incubated with another primary antibody to CD14 (dilution 1:100; Zymed Laboratories, San Francisco, CA), then incubated with fluorescein isothiocyanate isomer (FITC)-labeled secondary antibody. After washing with PBS, Cy5-labeled and FITC-labeled samples were examined using a fluorescence microscope (SZX12; Olympus, Tokyo, Japan).

Frequencies of double-positive cells were determined by histology experts counting these cells in entire specimens. Double-positive cells in the hepatic lobule were counted in five high-power fields (original magnification ×60). Cell counts are expressed as the mean ± SD in each specimen.

Statistical analysis

Statistical analysis were performed using SPSS for Windows version 11.0 software (SPSS, Chicago, IL, United States). Continuous variables are expressed as mean ± SD and the statistical significance of differences was determined using Student's *t* test. Comparisons between groups were made using the χ^2 test for categorical variables. Values of *P* < 0.05 were considered statistically significant.

RESULTS

The median follow-up for the 82 patients who underwent PD was 840 d (range, 183-2553 d). The frequency of NAFLD after PD was 36.6% (30/80). Clinical pre- and intraoperative data for patients with NAFLD (*n* = 30, 36.6%) and patients without NAFLD (*n* = 52, 63.4%) are summarized in Table 1. Univariate analysis identified cancer of the pancreatic head, sex, diameter of the main pancreatic duct (MPD) and dissection of the nerve plexus as factors associated with the development of NAFLD after PD.

Clinical postoperative data for patients with and without NAFLD are summarized in Table 2. The BMI, serum




Figure 1 Immunohistochemical staining of liver biopsy specimens for CD68 and CD14 (×60). Kupffer cells (CD68+) and lipopolysaccharide-sensitized Kupffer cells (CD14+) were compared between samples from conventional non-alcoholic fatty liver disease (NAFLD) and NAFLD after pancreatoduodenectomy (PD). Long arrows represent CD68+ Kupffer cells; Short arrows represent CD68+ and CD14+ Kupffer cells. A: Conventional NAFLD; B: NAFLD after PD.




Figure 2 Number of cells positive for CD68 (a marker of Kupffer cells) and CD14 (a marker of lipopolysaccharide-sensitized Kupffer cells). Conventional non-alcoholic fatty liver disease (NAFLD) and NAFLD after pancreatoduodenectomy (PD). Conventional NAFLD and NAFLD after PD specimens showed mean cell counts of 50.6 ± 4.0 and 104.3 ± 13.3 CD68+ Kupffer cells per individual, respectively (^a*P* < 0.05). Cell counts for CD14+ Kupffer cells were 0.6 ± 0.3 and 13.5 ± 4.2 cells per individual, respectively (^b*P* < 0.001).

Numbers of cells positive for CD68 (a marker of Kupffer cells) and CD14 (a marker of LPS-sensitized Kupffer cells) were counted in all biopsy specimens (Figure 1). The mean number of CD68+ cells per individual was 50.6 ± 4.0 in specimens from NAFLD associated with metabolic syndrome and 104.3 ± 13.3 in specimens from NAFLD after PD, indicating the presence of significantly more Kupffer cells in NAFLD after PD than in NAFLD associated with metabolic syndrome (*P* < 0.001) (Figure 2). CD14+ cells were observed in specimens from NAFLD associated with metabolic syndrome and in specimens from NAFLD after PD, with mean positive cell counts of 0.6 ± 0.3 and 13.5 ± 4.2, respectively, showing more LPS-sensitized Kupffer cells in NAFLD after PD than in NAFLD associated with metabolic syndrome (*P* < 0.001) (Figure 2). We also attempted to classify NAFLD into simple fatty liver or NASH. As for simple fatty liver, mean numbers of CD68+ cells and CD14+ cells per individual were 51.0 ± 6.8 and 0.4 ± 0.2, respectively, in specimens from fatty liver associated with metabolic syndrome and 116.0 ± 10.7 and 20.5 ± 2.5, respectively, in specimens from fatty liver after PD. This indicated the presence of more Kupffer cells and more LPS-sensitized Kupffer cells in specimens from simple fatty liver after PD than in specimens from simple fatty liver associated with metabolic syndrome (*P* < 0.001, CD68+ cells; *P* < 0.001, CD14+ cells). Regarding NASH, the mean numbers of CD68+ cells and CD14+ cells per individual were 50.2 ± 7.4 and 0.8 ± 0.6, respectively, in specimens from NASH associated with metabolic syndrome and 92.5 ± 19.5 and 6.5 ± 0.5, respectively, in specimens from NASH after PD. This showed that more Kupffer cells and more LPS-sensitized Kupffer cells were present in specimens from NASH after PD than in specimens from NASH associated with metabolic syndrome (CD68+ cells, *P* < 0.05; CD14+ cells, *P* < 0.05) (Figure 3). These observations suggest that after PD, Kupffer cells and LPS-sensitized Kupffer cells were significantly upregulated, not only in NASH, but also in simple fatty liver.

levels of total protein and albumin, and levels of cholinesterase, total cholesterol and insulin were significantly lower in patients with NAFLD after PD than in patients without NAFLD. Homeostasis model assessment for insulin resistance values, as an indicator of insulin resistance, and serum levels of triglycerides and HbA1c did not differ between these two groups.

At 6 mo postoperatively, 17 of the 30 patients (57%) with NAFLD after PD showed increased blood levels of AST. Of these 17 patients, we performed liver biopsies to pathologically examine specimens from four patients [mean serum levels of AST was 67 (54-80) U/L] who consented to undergo biopsies. Histopathological examination diagnosed two cases as stage 2 NASH, according to the Brunt criteria^[13], and two cases as moderate-to-severe macrovesicular steatosis.

In the 10 patients with NAFLD associated with metabolic syndrome, the mean serum level of AST was 56 (35-112) U/L. Five of 10 patients showed moderate-to-severe macrovesicular steatosis and the remaining five patients showed stage 2 NASH in histological examination.

DISCUSSION

Conventional NAFLD is thought to be caused by exces-




Figure 3 Number of cells positive for CD68 (a marker of Kupffer cells) and CD14 (a marker of lipopolysaccharide-sensitized Kupffer cells). Conventional fatty liver and fatty liver after pancreatoduodenectomy (PD), in conventional non-alcoholic steatohepatitis (NASH) and in NASH after PD. For simple steatosis, mean counts of CD68+ and CD14+ cells were 51.0 ± 6.8 and 0.4 ± 0.2 cells per individual in conventional fatty liver specimens, respectively, and 116.0 ± 10.7 and 20.5 ± 2.5 cells per individual, respectively, in fatty liver after PD specimens. This indicates more Kupffer cells and more lipopolysaccharide-sensitized Kupffer cells in simple fatty liver after PD specimens than in conventional simple fatty liver specimens (^b $P < 0.001$; ^d $P < 0.001$). Regarding NASH, mean cell counts for CD68+ cells and CD14+ cells were 50.2 ± 7.4 and 0.8 ± 0.6 cells per individual, respectively, in conventional NASH specimens, and 92.5 ± 19.5 and 6.5 ± 0.5 cells per individual, respectively, in NASH after PD specimens. This showed that more Kupffer cells and more LPS-sensitized Kupffer cells were present in NASH after PD specimens than in conventional NASH specimens (^a $P < 0.05$; ^c $P < 0.05$).

sive nutrition, lipid metabolic disorder and insulin resistance, as a part of metabolic syndrome^[4]. However, the present study demonstrated that NAFLD after PD was related to non-obese status, malnutrition and lack of hyperlipidemia and insulin resistance. These findings suggest that the mechanisms underlying NAFLD after PD differ from those causing NAFLD associated with metabolic syndrome. Recent studies have also suggested that pancreatic exocrine insufficiency may cause NAFLD after PD^[8,9]. Although only univariate analyses were examined in our study, pancreatic cancer was associated with the development of NAFLD, which is considered to lead to impaired pancreatic exocrine functions due to obstruction of the MPD, in turn resulting in obstructive distal pancreatic atrophy and fibrosis.

The clinical features of patients with NAFLD after PD resemble those in mice with MCD-induced NASH, in terms of the absence of obesity, insulin resistance and hypocholesterolemia^[14]. Increased fatty acid uptake and decreased hepatic export of triglycerides in the form of very-low-density lipoprotein (VLDL) represent two important mechanisms contributing to MCD-induced NASH^[14,15]. Malabsorption of essential amino acids such as choline due to pancreatic exocrine insufficiency may result in the development of NAFLD after PD.

NAFLD is often observed in patients showing hypoinsulinemia. Insulin inhibits lipolysis in adipose tissue and decreases the flux of free fatty acids (FFA) into plasma. In the absence of adequate insulin secretion, plasma FFA levels could conceivably be elevated due to increased adi-

pose tissue lipolysis and the liver would then be unable to adequately couple triglycerides to apoprotein B or secrete VLDL-triglyceride, resulting in hepatic steatosis^[16]. In this study, serum insulin concentrations were significantly lower in NAFLD after PD compared with non-NAFLD after PD. Insufficiency of insulin may be another factor contributing to the development of NAFLD after PD.

We performed liver biopsy in four patients with NAFLD after PD, diagnosing two cases of NASH. Kupffer cell counts have been shown to play important roles in the pathogenesis of NASH^[17]. Within the liver, Kupffer cells are major sources of tumor necrosis factor- α (TNF- α) produced in response to LPS^[12,18,19]. The process by which LPS activates Kupffer cells seems to be mediated by LPS-binding protein, CD14 and toll-like receptor 4^[20]. We therefore focused on CD14 expression in liver specimens from NAFLD after PD because the promoter polymorphism of CD14 has been reported as a risk factor for both alcoholic and non-alcoholic steatohepatitis^[21]. CD14 expression on Kupffer cells is low in the healthy human liver^[22,23] but increases in the presence of inflammatory liver disease^[24]. Expression of CD14 on Kupffer cells can be upregulated with LPS^[25,26]. A previous study reported that TNF- α production was decreased in genetically engineered CD14-deficient mice by down-regulating sensitivity to LPS^[27]. In contrast, the CD14 transgenic mice that overexpress CD14 on monocytes showed increased sensitivity to LPS^[28]. These changes in CD14 expression could represent a mechanism regulating liver sensitivity to LPS toxicity.

The present study demonstrated that Kupffer cells were significantly more common and LPS-induced CD14+ Kupffer cells were upregulated in NAFLD after PD specimens compared to NAFLD associated with metabolic syndrome specimens. Furthermore, even in simple fatty liver after PD specimens, more Kupffer cells and more LPS-sensitized Kupffer cells were present than in specimens from simple fatty liver associated with metabolic syndrome. These findings indicate that LPS plays a significant role in the occurrence of NAFLD after PD, even from an early stage.

Previous reports have hypothesized that the overgrowth of small intestinal bacteria might play a contributory role in NASH pathogenesis, particularly via a component of the gram-negative bacterial population, through the production of LPS^[29,33]. Among those patients who underwent PD, bacterial overgrowth may have occurred due to dissection around the SMA, leading to intestinal motor dysfunction and stasis, decreased secretion of gastric juices or blind loops.

The fatty liver is vulnerable to additional inflammatory insults, such as oxidative stress and gut-derived bacterial endotoxins, both of which can trigger hepatocellular inflammation and fibrosis^[34,35]. Accumulation of FFA in the liver due to malabsorption of essential amino acids such as choline and gut-derived LPS perhaps from intestinal bacterial overgrowth are important in the pathogenesis of NAFLD after PD.

In conclusion, NAFLD after PD is characterized, not only by malnutrition, but also by up-regulation of CD14 on Kupffer cells with hepatic steatosis. Our results suggest that gut-derived endotoxin contributes to the development of NAFLD after PD.

COMMENTS

Background

Non-alcoholic fatty liver disease (NAFLD), which sometimes develops after pancreatoduodenectomy (PD), is characterized by non-obesity and a lack of both hyperlipidemia and insulin resistance. The pathogenesis of NAFLD after PD may thus differ from the pathogenesis of NAFLD associated with metabolic syndrome.

Research frontiers

It was reported that the clinical features of the patients with NAFLD after PD are similar to those found in the murine non-alcoholic steatohepatitis model induced by a methionine-choline-deficient (MCD) diet. In mice fed the MCD diet, portal endotoxemia was observed. Thus, gut-derived factors such as lipopolysaccharide (LPS) appear to be related with NAFLD after PD. The authors hypothesized that gut-derived factors such as LPS might trigger the release of inflammatory cytokines from Kupffer cells, in turn mediating severe hepatic steatosis and liver injury after PD. The process by which LPS activates Kupffer cells seems to be mediated by LPS-binding protein, CD14 and toll-like receptor 4. The authors therefore focused on CD14 expression on Kupffer cells in liver specimens from cases of NAFLD after PD.

Innovations and breakthroughs

Unlike the patients with NAFLD associated with metabolic syndrome, the patients who developed NAFLD after PD showed significantly decreased levels of serum albumin, total protein, cholesterol and triglycerides, but no glucose intolerance or insulin resistance. Furthermore, the present study demonstrated that Kupffer cells were significantly more common and LPS-induced CD14+ Kupffer cells were upregulated in specimens of NAFLD after PD compared to specimens of NAFLD associated with metabolic syndrome. These findings indicate that LPS plays a significant role in the occurrence of NAFLD after PD. NAFLD after PD is characterized by both malnutrition and up-regulation of CD14 on Kupffer cells. Gut-derived endotoxin appears central to the development of NAFLD after PD.

Applications

Elucidation of the pathogenesis of NAFLD after PD may serve to prevent the development of NAFLD after PD.

Terminology

CD14: CD14 is the main LPS-receptor that can activate monocytes in conjunction with serum LPS-binding protein. CD14 expression on Kupffer cells is low in the healthy human liver but increases in the presence of inflammatory liver disease. Expression of CD14 on Kupffer cells can be upregulated with LPS.

Peer review

The authors investigated the pathogenesis of NAFLD after PD. The paper is well written overall.

REFERENCES

- Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. *Clin Liver Dis* 2009; **13**: 511-531 [PMID: 19818302 DOI: 10.1016/j.cld.2009.07.005]
- Angulo P. GI epidemiology: nonalcoholic fatty liver disease. *Aliment Pharmacol Ther* 2007; **25**: 883-889 [PMID: 17402991 DOI: 10.1111/j.1365-2036.2007.03246.x]
- Angulo P. Nonalcoholic fatty liver disease. *N Engl J Med* 2002; **346**: 1221-1231 [PMID: 11961152 DOI: 10.1056/NEJMr011175]
- Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. *Hepatology* 2003; **37**: 917-923 [PMID: 12668987 DOI: 10.1053/jhep.2003.50161]
- Pagano G, Pacini G, Musso G, Gambino R, Mecca F, De-petris N, Cassader M, David E, Cavallo-Perin P, Rizzetto M. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. *Hepatology* 2002; **35**: 367-372 [PMID: 11826410 DOI: 10.1053/jhep.2002.30690]
- Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. *Gastroenterology* 2001; **120**: 1183-1192 [PMID: 11266382 DOI: 10.1053/gast.2001.23256]
- Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. *Hepatology* 2010; **51**: 679-689 [PMID: 20041406 DOI: 10.1002/hep.23280]
- Kato H, Isaji S, Azumi Y, Kishiwada M, Hamada T, Mizuno S, Usui M, Sakurai H, Tabata M. Development of non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) after pancreaticoduodenectomy: proposal of a postoperative NAFLD scoring system. *J Hepatobiliary Pancreat Sci* 2010; **17**: 296-304 [PMID: 19809782 DOI: 10.1007/s00534-009-0187-2]
- Tanaka N, Horiuchi A, Yokoyama T, Kaneko G, Horigome N, Yamaura T, Nagaya T, Komatsu M, Sano K, Miyagawa S, Aoyama T, Tanaka E. Clinical characteristics of de novo nonalcoholic fatty liver disease following pancreaticoduodenectomy. *J Gastroenterol* 2011; **46**: 758-768 [PMID: 21267748 DOI: 10.1007/s00535-011-0370-5]
- Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. *Hepatology* 2010; **52**: 1836-1846 [PMID: 21038418 DOI: 10.1002/hep.24001]
- Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. *J Hepatol* 2007; **47**: 571-579 [PMID: 17644211 DOI: 10.1016/j.jhep.2007.04.019]
- Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. *Science* 1990; **249**: 1431-1433 [PMID: 1698311]
- Younossi ZM, Stepanova M, Rafiq N, Makhlof H, Younoszai Z, Agrawal R, Goodman Z. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. *Hepatology* 2011; **53**: 1874-1882 [PMID: 21360720 DOI: 10.1002/hep.24268]
- Rinella ME, Green RM. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. *J Hepatol* 2004; **40**: 47-51 [PMID: 14672613 DOI: 10.1016/j.jhep.2003.09.020]
- Rinella ME, Elias MS, Smolak RR, Fu T, Borensztajn J, Green RM. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. *J Lipid Res* 2008; **49**: 1068-1076 [PMID: 18227531 DOI: 10.1194/jlr.M800042-JLR200]
- Soliman AT, Alsalmi I, Asfour M. Hypoinsulinaemia has an important role in the development of oedema and hepatomegaly during malnutrition. *J Trop Pediatr* 1996; **42**: 297-299 [PMID: 8936962 DOI: 10.1093/tropej/42.5.297]
- Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. *N Engl J Med* 2000; **343**: 1467-1476 [PMID: 11078773 DOI: 10.1056/NEJM200011163432007]
- Su GL. Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. *Am J Physiol Gastrointest Liver Physiol* 2002; **283**: G256-G265 [PMID: 12121871 DOI: 10.1152/ajpgi.00550.2001]
- Kremer M, Thomas E, Milton RJ, Perry AW, van Rooijen N, Wheeler MD, Zacks S, Fried M, Rippe RA, Hines IN. Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis. *Hepatology* 2010; **51**: 130-141

- [PMID: 20034047 DOI: 10.1002/hep.23292]
- 20 **Cubero FJ**, Nieto N. Ethanol and arachidonic acid synergize to activate Kupffer cells and modulate the fibrogenic response via tumor necrosis factor alpha, reduced glutathione, and transforming growth factor beta-dependent mechanisms. *Hepatology* 2008; **48**: 2027-2039 [PMID: 19003881 DOI: 10.1002/hep.22592]
 - 21 **Brun P**, Castagliuolo I, Floreani AR, Buda A, Blasone L, Palù G, Martines D. Increased risk of NASH in patients carrying the C(-159)T polymorphism in the CD14 gene promoter region. *Gut* 2006; **55**: 1212 [PMID: 16849359 DOI: 10.1136/gut.2006.093336]
 - 22 **Antal-Szalmás P**. Evaluation of CD14 in host defence. *Eur J Clin Invest* 2000; **30**: 167-179 [PMID: 10651843 DOI: 10.1046/j.1365-2362.2000.00610.x]
 - 23 **Takai N**, Kataoka M, Higuchi Y, Matsuura K, Yamamoto S. Primary structure of rat CD14 and characteristics of rat CD14, cytokine, and NO synthase mRNA expression in mononuclear phagocyte system cells in response to LPS. *J Leukoc Biol* 1997; **61**: 736-744 [PMID: 9201265]
 - 24 **Tomita M**, Yamamoto K, Kobashi H, Ohmoto M, Tsuji T. Immunohistochemical phenotyping of liver macrophages in normal and diseased human liver. *Hepatology* 1994; **20**: 317-325 [PMID: 7519162]
 - 25 **Ziegler-Heitbrock HW**, Ulevitch RJ. CD14: cell surface receptor and differentiation marker. *Immunol Today* 1993; **14**: 121-125 [PMID: 7682078]
 - 26 **Matsuura K**, Ishida T, Setoguchi M, Higuchi Y, Akizuki S, Yamamoto S. Upregulation of mouse CD14 expression in Kupffer cells by lipopolysaccharide. *J Exp Med* 1994; **179**: 1671-1676 [PMID: 7513013]
 - 27 **Haziot A**, Ferrero E, Lin XY, Stewart CL, Goyert SM. CD14-deficient mice are exquisitely insensitive to the effects of LPS. *Prog Clin Biol Res* 1995; **392**: 349-351 [PMID: 8524940]
 - 28 **Ferrero E**, Jiao D, Tsuberi BZ, Tesio L, Rong GW, Haziot A, Goyert SM. Transgenic mice expressing human CD14 are hypersensitive to lipopolysaccharide. *Proc Natl Acad Sci USA* 1993; **90**: 2380-2384 [PMID: 7681594]
 - 29 **Lewis JR**, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. *Dig Dis Sci* 2010; **55**: 560-578 [PMID: 20101463 DOI: 10.1007/s10620-009-1081-0]
 - 30 **Shanab AA**, Scully P, Crosbie O, Buckley M, O'Mahony L, Shanahan F, Gazareen S, Murphy E, Quigley EM. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. *Dig Dis Sci* 2011; **56**: 1524-1534 [PMID: 21046243 DOI: 10.1007/s10620-010-1447-3]
 - 31 **Miele L**, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Mascianà R, Forgione A, Gabrieli ML, Perotti G, Vecchio FM, Rapaccini G, Gasbarrini G, Day CP, Grieco A. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. *Hepatology* 2009; **49**: 1877-1887 [PMID: 19291785 DOI: 10.1002/hep.22848]
 - 32 **Wu WC**, Zhao W, Li S. Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats. *World J Gastroenterol* 2008; **14**: 313-317 [PMID: 18186574 DOI: 10.3748/wjg.14.313]
 - 33 **Spruss A**, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. *Hepatology* 2009; **50**: 1094-1104 [PMID: 19637282 DOI: 10.1002/hep/23122]
 - 34 **Nazim M**, Stamp G, Hodgson HJ. Non-alcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth. *Hepatogastroenterology* 1989; **36**: 349-351 [PMID: 2516007]
 - 35 **Gao Y**, Song LX, Jiang MN, Ge GY, Jia YJ. Effects of traditional chinese medicine on endotoxin and its receptors in rats with non-alcoholic steatohepatitis. *Inflammation* 2008; **31**: 121-132 [PMID: 18302012 DOI: 10.1007/s10753-008-9057-3]

P- Reviewers Sookoian SC, Hudacko RM **S- Editor** Song XX
L- Editor Roemmele A **E- Editor** Li JY

